BUSINESS SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:

	2015		2014		2013
McKesson Corporation	21	%	20	%	19	%
AmerisourceBergen Corporation	16	%	17	%	15	%
Cardinal Health, Inc.	12	%	12	%	14	%

Selected geographic area information was as follows:

	Revenues						Property, Plant and Equipment
Dollars in Millions	2015		2014		2013		2015		2014
United States	$	8,188	$	7,716	$	8,318	$	3,681	$	3,686
Europe	3,491		3,592		3,930		616		597
Rest of the World	4,142		3,459		3,295		115		134
Other(a)	739		1,112		842		—		—
Total	$	16,560	$	15,879	$	16,385	$	4,412	$	4,417

(a) Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.

Product revenues were as follows:

	Year Ended December 31,
Dollars in Millions	2015		2014		2013
Virology
Baraclude (entecavir)	$	1,312	$	1,441	$	1,527
Hepatitis C Franchise	1,603		256		—
Reyataz (atazanavir sulfate) Franchise	1,139		1,362		1,551
Sustiva (efavirenz) Franchise	1,252		1,444		1,614
Oncology
Empliciti (elotuzumab)	3		—		—
Erbitux* (cetuximab)	501		723		696
Opdivo (nivolumab)	942		6		—
Sprycel (dasatinib)	1,620		1,493		1,280
Yervoy (ipilimumab)	1,126		1,308		960
Neuroscience
Abilify* (aripiprazole)	746		2,020		2,289
Immunoscience
Orencia (abatacept)	1,885		1,652		1,444
Cardiovascular
Eliquis (apixaban)	1,860		774		146
Mature Products and All Other	2,571		3,400		4,878
Total Revenues	$	16,560	$	15,879	$	16,385

The composition of total revenues was as follows:

	Year Ended December 31,
Dollars in Millions	2015		2014		2013
Net product sales	$	14,045	$	11,660	$	12,304
Alliance revenues	2,408		3,828		3,804
Other revenues	107		391		277
Total Revenues	$	16,560	$	15,879	$	16,385